trial · primary record
VS-6766
Solid Tumours
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 104 |
| Primary completion | 2025-10-15 |
| Primary endpoint | Recommended Phase 2 Dose (RP2D) of VS-6766 |
| Registry ID | NCT02407509 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:08.275Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02407509
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.